Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28515723 | 0.85 | SLC6A3 (0.52) | SIGMAR1CHRM2CHRM1LTA4H | |
| SCHEMBL8084554 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RNPSR1GAACHRM2 | |
| SCHEMBL28795567 | 0.84 | SIGMAR1 (0.51) | SIGMAR1MC4RNPSR1 | |
| SCHEMBL8084551 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RNPSR1GAACHRM2 | |
| SCHEMBL8091680 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RNPSR1GAACHRM2 | |
| SCHEMBL2196462 | 0.83 | SIGMAR1 (0.59) | SIGMAR1MC4RNPSR1GAACHRM2 | |
| SCHEMBL19713576 | 0.83 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15961293 | 0.82 | KCNH2 (0.61) | SIGMAR1DRD2 | |
| SCHEMBL15961225 | 0.82 | SIGMAR1 (0.62) | SIGMAR1MC4RRAB9AGAAPOLB | |
| SCHEMBL27674510 | 0.82 | ALDH1A1 (0.50) | SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | SIGMAR1 4220/4885MC4R 3945/4885RAB9A 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.